Clinical Trials Browser

Advanced Solid Tumors

NCT05379595 2026-04-13

OrigAMI-1

Phase 1/2 Recruiting

225 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT06469944 2026-04-13

MK-3475-06C

Phase 1/2 Recruiting

160 enrolled

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

NCT05919264 2026-04-09

FOG-001 in Locally Advanced or Metastatic Solid Tumors

Phase 1/2 Recruiting

595 enrolled

CNSGastrointestinalGenitourinaryGynecologicSarcoma

Craniopharyngioma, Carcinoma, Hepatocellular, Neoplasm Metastasis, Neoplasms, Adenomatous Polyposis Coli, Prostatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Desmoid Tumors

Clinical Trials

A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors

OrigAMI-1

MK-3475-06C

FOG-001 in Locally Advanced or Metastatic Solid Tumors

PANGEA

MK-3475-06E

Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer

Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma

BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours

MK-9999-02A

Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Cancer

5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.

A Study of YL242 in Subjects With Advanced Solid Tumors

A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors

A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors

Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer

Establishing Best Treatment Strategy for T4 Esophageal Cancer

AK129 Combination Therapy for Advanced Solid Tumors

HAICI

Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab

Liposomal Irinotecan + Oxaliplatin + Bevacizumab Versus Liposomal Irinotecan + 5-FU/LV

A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors